β-Lactoglobulin-Modified Mesoporous Silica Nanoparticles: A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostate Cancer Cells

The clinical utilization of fenbendazole (FBZ) as a potential anticancer drug has been limited due to its low water solubility, which causes its low bioavailability. The development of a drug nanoformulation that includes the solubilizing agent as a drug carrier can improve solubility and bioavailab...

Descripción completa

Detalles Bibliográficos
Autores principales: Koohi Moftakhari Esfahani, Maedeh, Alavi, Seyed Ebrahim, Cabot, Peter J., Islam, Nazrul, Izake, Emad L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024783/
https://www.ncbi.nlm.nih.gov/pubmed/35456716
http://dx.doi.org/10.3390/pharmaceutics14040884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024783/
https://www.ncbi.nlm.nih.gov/pubmed/35456716
http://dx.doi.org/10.3390/pharmaceutics14040884

Ejemplares similares